The objective of the project was to examine the effects of CBD on canine cancer cell growth proliferation with aims towards understanding the signaling pathways involved and the apoptotic response related to CBD. A second aim was to understand the influence of CBD co-treatment with chemotherapeutics such as doxorubicin and vincristine. Continue reading “Research Update CHF 02643-A Final: Examination of the Effects of Cannabidiol on Canine Neoplastic Cell Apoptosis/Autophagy and Potential for Chemotherapy Resistance or Sensitivity”
Between February 2019 and March 2020, 56 dogs were enrolled in the study. The amount of Δ9- tetrohydrocannabinol (THC) ingested was available for eight dogs (14%). The average dose ingested for those dogs was 175 mg (range 35-4,400). Types of sources reported included both commercial and homemade edible products (15), marijuana plant material (3), and commercial THC concentrate (1). Continue reading “Research Update CHF 02692-A Final: Diagnostic Accuracy of Point of Care Analysis of Canine Urine and Plasma in Marijuana Toxicosis”
We developed a comprehensive method for detecting infectious diseases in dogs, taking the guesswork out of determining which tests to use for diagnosis, and potentially improving disease surveillance because of the comprehensive nature of the test. The method is a targeted next-generation sequencing (NGS) assay, which takes advantage of the amount of data that can be generated with NGS but also includes a PCR step prior to sequencing. This reduces costs associated with the sequencing and provides adequate turn-around time for diagnostic use. Continue reading “Research Update CHF 02553 Final: Targeted Next Generation Sequencing Panel for Comprehensive Testing of Vector-borne Pathogens”
Diagnostic tests based on the detection of DNA from harmful organisms in clinical samples have revolutionized veterinary medicine in the last decades. Currently, diagnostic panels for several vectorborne diseases (VBDs) are available through universities and private labs in the USA and abroad. Continue reading “Research Update CHF 02528 EY3: Developing a Next Generation Sequencing Diagnostic Platform for Tick-Borne Diseases”
The preparations for the CBD epilepsy study were started in December 2017, including hiring a full-time research assistant and part-time work/study student, creating all of the study documents necessary for the trial, and creating a newsletter/announcement for Colorado veterinarians. We began enrolling patients for the study at the end of January 2018. We anticipated enrolling 20 patients per year; we have completed the anticipated enrollment of 60 dogs. Additionally, we have been working with outside clinics in Colorado to help us in the enrollment process of the study. Three local specialty clinics with board-certified neurologists are conducting the study with CSU’s oversight at their hospitals and general veterinarians are helping with the recheck appointments and blood draws. Continue reading “Research Update CHF 02323 Final: Efficacy of Cannabidiol (CBD) for the Treatment of Canine Epilepsy”
To date, we have screened 31 dogs for the SLIM study. Of these, 23 have met the inclusion criteria and were enrolled. Of these enrolled dogs, six dogs have completed at least 12 weeks of the 24-week clinical trial. We are averaging 1-2 dogs screening for the study per week. Therefore, we are currently on track to have all dogs enrolled by Fall 2021. Continue reading “Research Update CHF 02723 EY1: Scientific and Clinical Assessment of Fecal Microbiota Transplant in Obese Dogs: SLIM Study”
We enrolled 30 dogs with mild to moderate atopic dermatitis and 30 healthy control animals in the study. The dogs with atopic dermatitis were treated with either Apoquel® (n=17) or Cytopoint® (n=10), whereas one dog was switched from Apoquel® to Cytopoint®, one dog was treated with prednisone followed by Apoquel®, and one dog was treated with a topical shampoo. Both Apoquel® and Cytopoint® reduced the clinical severity of the skin lesions during 8 weeks of treatment. Continue reading “Research Update CHF 02651 Final: Discovery of Novel Biomarkers of Canine Atopic Dermatitis through Lipid Profiling”
Data collected over the 15 years of the 9/11 study represents a massive amount of never before available information on the short and long-term impacts of a search & rescue deployment on the health and behavior of the search dog. Continue reading “Research Update CHF 02322 End-Year 4: Analysis of the Health, Behavioral, and Longevity Data Collected in the 9/11 Medical Surveillance Longitudinal Study”
We have met our Labrador Retriever recruitment for this study over the past six months. We will continue to complete DNA isolation and marker genotyping of the remaining dogs needed for the study as long as the genotyping service remains open under the Covid-19 pandemic. Public engagement with the project continues to be good.
Over the next 6 months, we will focus on finalizing the marker data set for the study for which we do not yet have SNP genotypes. We will then undertake the computing needed to robustly estimate the heritability of cruciate ligament rupture in the Labrador Retriever and further advance prediction of risk of disease using the genomic marker data.
Our final data set is expected to include more than 1,000 Labrador Retriever dogs as promised under the award. We are extremely grateful for the outstanding engagement with this project by the community of Labrador Retriever owners and breeders that we work with.
April 18, 2021 07:00 ET — The Portuguese Water Dog Foundation is excited to kick off a new research study to investigate the genetics of Addison’s disease — specifically in PWDs! The study will be conducted by Drs. Steven Friedenberg and Leigh Anne Clark and their research team at the University of Minnesota College of Veterinary Medicine and Clemson University.